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Abstract 
The selective apoptotic elimination of autoreactive T cells in the central nervous system (CNS) 
contributes to the resolution of inflammation and the spontaneous clinical recovery from experimental 
autoimmune encephalomyelitis (EAE). To assess the molecular mechanisms involved in this process, 
we used three-colour flow cytometry to examine the expression of apoptosis-regulating proteins by 
inflammatory cells isolated from the spinal cords of Lewis rats immunized with myelin basic protein 
(MBP) and complete Freund's adjuvant. Throughout the course of the disease, which peaked 12–14 
days after inoculation and was followed by clinical recovery, we analyzed the DNA content of the 
spinal cord inflammatory cells to assess apoptosis and, simultaneously, we measured the expression of 
five proteins (Fas, Fas ligand (Fas-L), Bcl-2, Bcl-x and Bax) which modulate the apoptotic process. 
Cells expressing the death effector molecules Fas and Fas-L were particularly prone to undergo 
apoptosis, and were over-represented in the apoptotic population. Of the cells expressing the cell death 
inhibitor Bcl-2, a low proportion were undergoing apoptosis compared to the proportion of the total 
inflammatory cell population undergoing apoptosis, indicating that expression of Bcl-2 protects against 
T cell apoptosis in this disease. There was no evidence, however, that the apoptotic regulators Bcl-x 
and Bax influenced the susceptibility to apoptosis. We also found that V 8.2+ T cells, which constitute 
the predominant encephalitogenic MBP-reactive T cell population in the Lewis rat, have a high 
frequency of Fas and Fas-L expression compared to other inflammatory cells. This would account for 
the previously demonstrated susceptibility of V 8.2+ T cells to apoptosis in the CNS in EAE. These 
findings support the hypothesis that autoreactive T cells are eliminated from the CNS during 
spontaneous recovery from EAE by activation-induced apoptosis involving the Fas pathway.  
Author Keywords: T cell apoptosis; Fas (CD95); experimental autoimmune encephalomyelitis; Bcl-
2; autoimmunity  
 
 
1. Introduction 
T cell apoptosis (programmed cell death) occurs in the central nervous system (CNS) in 
experimental autoimmune encephalomyelitis (EAE) (Pender et al., 1991 and Pender et al., 
1992; Schmied et al., 1993). This T-cell-mediated demyelinating disease of the CNS is the 
best available animal model of multiple sclerosis, and can be induced in susceptible animals 
by immunization with myelin antigens, such as myelin basic protein (MBP), and adjuvants or 
by the passive transfer of T lymphocytes activated by these antigens (Pender, 1995). In acute 
EAE in the Lewis rat, encephalitogenic V 8.2+ MBP-reactive T cells are selectively 
eliminated from the CNS by apoptosis (Tabi et al., 1994 and Tabi et al., 1995; McCombe et 
al., 1996a), with resultant resolution of inflammation and clinical recovery. 
We have proposed that the mechanism responsible for the apoptosis of autoreactive T 
lymphocytes in the target organ of this autoimmune disease is activation-induced cell death 
due to the interaction of previously activated T cells with non-professional antigen-presenting 
cells (APCs) in the CNS, such as astrocytes or microglia, which fail to deliver the 
costimulatory signal needed for T cell survival(Pender et al., 1992; Tabi et al., 1994 and Tabi 
et al., 1995). This hypothesis is supported by our finding that the selective apoptosis of V
8.2+ T cells in the CNS in EAE is reduced by dexamethasone, which inhibits activation-
induced cell death (McCombe et al., 1996b). It is also supported by in vitro experiments 
demonstrating that CD4+ MBP-specific T cell lines undergo apoptosis after reactivation by 
activated microglia but proliferate after reactivation by non-microglial CNS macrophages 
(Ford et al., 1996). Furthermore, antigen presentation by astrocytes in vitro has been shown to 
increase the susceptibility of T lymphocytes to apoptosis (Gold et al., 1996). 
Recent research has revealed important insights into the molecular biology of apoptosis. The 
interaction of Fas and Fas ligand (Fas-L) is required for the activation-induced death of 
previously stimulated T cells (Russell et al., 1993; Russell and Wang, 1993; Bossu et al., 
1993; Alderson et al., 1995). Fas (APO-1 or CD95) is a cell surface protein that induces 
apoptosis via activation of cysteine proteases (caspases) (Fraser and Evan, 1996). A soluble 
secreted form of Fas has also been identified (Cheng et al., 1994). Its natural ligand, Fas-L, is 
primarily expressed on the cell surface, but overexpression causes shedding of the protein in a 
soluble form (Suda et al., 1993). Activation of T lymphocytes increases their expression of 
Fas and induces their expression of Fas-L within 24 h, and they become susceptible to Fas-
mediated apoptosis 3–4 days after activation (Brunner et al., 1995; Ju et al., 1995; Dhein et 
al., 1995). 
Other gene products which modulate lymphocyte apoptosis are those of the Bcl-2 family. Bcl-
2, which is chiefly expressed on the mitochondrial outer membrane, is an effective inhibitor 
of apoptosis in many systems. Bcl-x is homologous to Bcl-2, and has long (Bcl-x ), short 
(Bcl-x ) and transmembrane region-negative forms (Bcl-x ), the latter two forms being 
the result of alternative splicing (Fang et al., 1994). The bulk of the Bcl-x  protein, like Bcl-
2, is localized in the periphery of mitochondria, and it and Bcl-x  have also been shown 
to prevent cell death. In contrast, Bcl-x  appears to facilitate apoptosis by inhibiting the 
death suppressor activity of Bcl-2 (Boise et al., 1993; Fang et al., 1995), as does Bax, an 
intracellular protein that forms heterodimers with Bcl-2 and Bcl-x (Oltvai et al., 1993; Vaux 
and Strasser, 1996). Thus, the response of a cell to death signals is modulated by the 
differential expression and interaction of inhibitors and facilitators of apoptosis (Núñez et al., 
1994). 
The present study was performed to assess the roles of five apoptosis-regulating proteins (Fas, 
Fas-L, Bcl-2, Bcl-x and Bax) in the apoptosis of T lymphocytes in the spinal cords of Lewis 
rats with acute EAE induced by immunization with MBP and complete Freund's adjuvant. 
Using three-colour flow cytometry, we demonstrate that Fas+ cells and Fas-L+ cells are 
particularly prone to apoptosis, whereas Bcl-2+ cells are protected against apoptosis in the 
CNS. Furthermore, V 8.2+ T cells, which constitute the predominant encephalitogenic MBP-
reactive T cell population in the Lewis rat (Chluba et al., 1989; Burns et al., 1989; Imrich et 
al., 1995), have a high frequency of Fas and Fas-L expression, which increases their 
susceptibility to apoptosis. These findings support the hypothesis that autoreactive T cells are 
eliminated from the CNS during spontaneous recovery from EAE by activation-induced 
apoptosis involving the Fas pathway, and may have implications for the design of therapeutic 
strategies to facilitate this process. 
 
2. Materials and methods 
2.1. Animals 
Female Lewis rats (JC strain), 7–10 weeks old, were obtained from the Central Animal 
Breeding House of the University of Queensland. 
2.2. Preparation of inoculum and induction of EAE 
MBP was prepared from guinea pig brains by the method of Deibler et al. (1972). MBP in 
0.9% saline was emulsified in an equal volume of incomplete Freund's adjuvant containing 4 
mg/ml Mycobacterium butyricum. Under anaesthesia, rats were inoculated in one hind 
footpad with 0.1 ml emulsion. The total dose of MBP was 50 g per rat. 
2.3. Clinical assessment 
Tail, hindlimb and forelimb weakness were each graded on a scale of 0 (no weakness) to 4 
(total paralysis) as previously described (Pender, 1986). The total clinical score was obtained 
by adding these three scores (maximum=12). 
2.4. Extraction of cells from the spinal cord 
Using our previously described methods (Tabi et al., 1994), cells were isolated from the 
spinal cords of rats perfused with ice-cold saline. The entire spinal cord was removed by 
insufflation, weighed, and a single cell suspension in ice-cold RPMI containing 1% foetal calf 
serum (FCS) was prepared by passage of the spinal cord through a 200-mesh stainless steel 
sieve. The cell suspension was mixed with isotonic Percoll (Percoll:HBSS 9:1) in a 3:2 ratio 
(density 1.052) in 50 ml centrifuge tubes and spun for 25 min at 640×g at 4°C. The cell pellet 
and the last 9 ml supernatant were resuspended, transferred to a conical centrifuge tube, 
underlaid with 1 ml Ficoll and spun for 20 min at 600×g at 4°C. The cells from the interface 
above the Ficoll were collected, washed and counted. To enrich for T lymphocytes, the cells 
were then passed through a nylon wool column, as previously described (Tabi et al., 1994). 
2.5. Antibodies 
Mouse monoclonal antibody to V 8.2 (R78) was kindly provided by Dr. T. Hünig (Torres-
Nagel et al., 1993). Rabbit polyclonal antibodies specific for rat Fas (M-20), Fas-L (W-20), 
Bcl-2 (N19), Bcl-x /  (L-19) and Bax (P19) were purchased from Santa Cruz 
Biotechnology. Western blot analysis of the CNS inflammatory cell protein extract confirmed 
the specificity of antibody binding and indicated that Bcl-x  was the predominant form of 
Bcl-x expressed (not shown). The secondary antibodies employed were fluorescein 
isothiocyanate (FITC)-conjugated goat anti-rabbit IgG F(ab′)2 (Rockland) and phycoerythrin 
(PE)-conjugated goat anti-mouse Ig (Dako). Mouse IgG1 (Dako) and rabbit IgG (Rockland) 
were used as control antibodies. The primary and secondary antibodies were diluted in 
phosphate-buffered saline (PBS)/azide (1% FCS/1% sodium azide in PBS) plus 10% 
autologous rat serum. 
2.6. Labelling of cells and flow cytometric analysis 
Three-colour analysis was used for the simultaneous detection of surface and intracellular 
antigens and for analysis of DNA content for assessment of apoptosis. Each sample was 
stained with the following: propidium iodide (PI) which stains DNA; the anti-V 8.2 antibody 
followed by PE-conjugated secondary antibody; and an antibody against one of the five 
apoptosis-regulating proteins followed by an FITC-conjugated secondary antibody. Briefly, 
105–106 cells were stained for expression of the cell-surface antigens V 8.2, Fas and Fas-L as 
previously described (McCombe et al., 1996a). After washing to remove unbound secondary 
antibody, cells were fixed with 1 ml ice-cold 0.25% paraformaldehyde in PBS (pH 7.2) 
overnight at 4°C. They were then washed in PBS and permeabilized by being gently 
resuspended in 1 ml 0.2% Tween 20 in PBS and incubated at 37°C for 15 min. Samples were 
washed, and the intracellular antigens Bcl-2, Bcl-x /  and Bax were labelled in the same 
manner as for the surface antigens. 
The washed samples were then resuspended in an appropriate volume (100–300 l) of PI-
staining solution which was freshly prepared by diluting stock solution (RNase (5 mg/ml) and 
PI (250 g/ml) in 0.1 M PBS containing 0.1 mM EDTA, pH 7.4) with PBS/azide. Samples 
were kept on ice in the dark and analyzed within 1 h. Immunofluorescence and DNA analysis 
were performed on a Becton Dickinson FACSCalibur using CellQuest software. Electronic 
compensation for three-colour analysis ensured unchanged FITC and PE distributions 
following PI labelling of DNA. For each sample, 40000 events were scored. To avoid 
detecting nuclear debris, events with a low level of PI fluorescence were not collected (see 
Fig. 1B). For surface and intracellular antigen labelling, the Ig-control sample values were 
subtracted from all other sample values to remove FITC and PE background fluorescence. 
Apoptotic events were defined as those having lower PI fluorescence than the sharply defined 
G0/G1 peak.  
 Fig. 1. (A) Representative flow cytometric plots of apoptosis-regulating protein and V 8.2 expression 
by CNS-infiltrating cells extracted from the spinal cords of rats with EAE 14 days after inoculation. 
The upper boxed area in each plot defines the positively labelled cells. (B) DNA staining profiles of the 
total inflammatory cell population (total cells) and the positively labelled populations shown in A. 
2.7. Statistical analysis 
Percentages of the different inflammatory cell populations which were apoptotic were 
compared using analysis of variance (ANOVA) to compare all the groups on each day 
simultaneously, followed by Student's t-test to compare each cell population against the total 
inflammatory cell population.  
3. Results 
3.1. Course of disease 
Rats developed neurological signs of EAE 10–12 days after inoculation. The peak of disease 
was on days 12–14, after which the rats gradually recovered. The mean total clinical scores at 
the time of study are shown in Table 1. On each day after inoculation we analyzed the cells 
from 2–4 groups of rats, with each group containing the pooled spinal cord inflammatory cells 
extracted from 5–7 rats.  
 
3.2. Apoptosis of cells expressing apoptosis-regulating proteins 
To determine the susceptibility to apoptosis of cells expressing different apoptosis-regulating 
proteins, we employed simultaneous flow cytometric analysis of surface and intracellular 
antigens and DNA content. Cells expressing Fas or Fas-L tended to be smaller in size (FSC) 
than cells not expressing these proteins (Fig. 1A). This is explained by the apoptotic 
shrinkage of Fas+ cells and Fas-L+ cells which, as the DNA profiles show (Fig. 1B), have an 
increased susceptibility to apoptosis compared to the total inflammatory cell population. In 
contrast, Bcl-2+ cells tended to be larger than Bcl-2− cells, which is explained by the relative 
resistance of Bcl-2+ cells to apoptosis (Fig. 1B). The proportions of Fas+ cells and Fas-L+ cells 
undergoing apoptosis were higher than the proportion of total inflammatory cells undergoing 
apoptosis on every day from day 11 to day 18 after inoculation (Fig. 2), indicating that Fas+ 
cells and Fas-L+ cells are highly vulnerable to apoptosis throughout the course of EAE. The 
resistance of Bcl-2+ cells to apoptosis was also evident throughout the course of EAE (Fig. 2). 
The expression of Bcl-x or Bax did not appear to influence susceptibility to apoptosis (Fig. 
1B and Fig. 2).   
 Fig. 2. Percentages of CNS-infiltrating cells expressing apoptosis-regulating proteins that were 
apoptotic in rats with EAE on days 11–18 after inoculation. Cells were extracted from the spinal cord 
and immunostained for flow cytometry analysis. The mean and population standard deviation of the 
proportion of positively stained cells that was apoptotic on each day were then calculated. The 
ANOVA P-values for the overall comparison of the responses of the six cell populations on each day, 
together with the P-values (Student's t-test) for the comparisons of selected pairs of cell populations, 
are shown directly below the day to which they refer (ND=not determined because of insufficient data).  
The vulnerability of Fas+ cells and Fas-L+ cells to apoptosis was also indicated by enrichment 
of Fas+ cells and Fas-L+ cells in the apoptotic compared to the non-apoptotic populations 
(Table 2). The proportion of Fas+ cells in the apoptotic population was 3.0–6.4 times the 
proportion of Fas+ cells in the non-apoptotic population. Even more strikingly, the proportion 
of Fas-L+ cells in the apoptotic population was 4.2–15.9 times the proportion in the non-
apoptotic population. In contrast to Fas+ cells and Fas-L+ cells, Bcl-2+ cells were consistently 
under-represented in the apoptotic population (Table 2), indicating that they are protected 
against apoptosis. The proportions of cells expressing Bcl-x or Bax were similar in the 
apoptotic and non-apoptotic populations. 
 3.3. Expression of apoptosis-regulating proteins by V 8.2+ T 
lymphocytes 
We have previously presented evidence that encephalitogenic V 8.2+ MBP-specific T cells 
are selectively eliminated from the CNS by apoptosis during spontaneous recovery from 
EAE, induced by the passive transfer of V 8.2+ MBP-reactive T cells (Tabi et al., 1994) or by 
immunization with MBP and complete Freund's adjuvant (McCombe et al., 1996a). We 
therefore examined the expression of apoptosis-regulating proteins by the disease-relevant 
V 8.2+ T cells in the CNS, which comprised up to 10.6% of the total inflammatory cells at 
the peak of disease and down to 1.1% at recovery (data not shown). As illustrated in Fig. 3, 
the proportions of Fas+ cells and Fas-L+ cells in the V 8.2+ population were 1.4–5.8 and 1.5–
8.8 times, respectively, the proportions of these cells in the non-V 8.2+ population. The 
proportions of V 8.2+ cells expressing Fas or Fas-L were highest during the later recovery 
phase of the disease (16–18 days after inoculation). The proportions of Bcl-2+, Bcl-x+ and 
Bax+ cells in the V 8.2+ population also tended to be higher than the proportions of these 
cells in the non-V 8.2+ population (results for Bcl-2+ cells are shown in Fig. 3). Furthermore, 
the proportions of Fas+V 8.2+ cells that were apoptotic were 6.4 and 4.4 times the 
proportions of Fas−V 8.2+ cells that were apoptotic 13 and 14 days after inoculation, 
respectively (day 13 was the time of maximal apoptosis; see Fig. 2), and the proportions of 
Fas-L+V 8.2+ cells that were apoptotic were 2.9 and 4.9 times the proportions of Fas-L−V
8.2+ cells that were apoptotic on these days (Table 3). The proportions of Bcl-2+V 8.2+ cells 
that were apoptotic were 0.9 and 0.4 times the proportions of Bcl-2−V 8.2+ cells that were 
apoptotic on days 13 and 14 after inoculation respectively (Table 3). These results indicate 
that V 8.2+ cells expressing Fas or Fas-L are highly vulnerable to apoptosis, whereas V 8.2+ 
cells expressing Bcl-2 are protected against apoptosis.  
 Day Post-Inoculation 
Fig. 3. Percentages of V 8.2+ and non-V 8.2+ CNS-infiltrating cells expressing apoptosis-regulating 
proteins in rats with EAE on days 11–18 after inoculation. 
 
4. Discussion 
In the present study we have shown that CNS-infiltrating cells expressing Fas or Fas-L were 
highly vulnerable to apoptosis during the course of acute EAE, whereas Bcl-2-expressing 
cells appeared to be relatively protected against apoptosis. V 8.2+ T cells, which constitute 
the predominant encephalitogenic MBP-reactive T cell population in the Lewis rat (Chluba et 
al., 1989; Burns et al., 1989; Imrich et al., 1995), expressed Fas and Fas-L more frequently 
than did other inflammatory cells in the CNS. Furthermore, V 8.2+ cells expressing Fas or 
Fas-L were highly vulnerable to apoptosis compared to V 8.2+ cells not expressing these 
proteins. These findings account for the previously demonstrated susceptibility of V 8.2+ T 
cells to apoptosis in the CNS during recovery from acute EAE (Tabi et al., 1994; McCombe 
et al., 1996a). The present findings support our hypothesis that autoreactive T cells are 
eliminated from the CNS by activation-induced apoptosis (Pender et al., 1992; Tabi et al., 
1994 and Tabi et al., 1995), which is mediated in previously activated T cells by the 
interaction of Fas and Fas-L (Bossu et al., 1993; Russell and Wang, 1993; Russell et al., 1993; 
Alderson et al., 1995). The ligation of Fas on the surface of the T cell can be mediated by Fas-
L on the same T cell or by Fas-L expressed by other cells (Brunner et al., 1995; Dhein et al., 
1995). Only a low proportion of the cells expressing the death inhibitor Bcl-2 underwent 
apoptosis compared to the total spinal cord inflammatory cell population, indicating that 
expression of Bcl-2 protects against apoptosis. Bcl-2 is known to inhibit Fas-mediated 
apoptosis in some cell types (Itoh et al., 1993; Yoshino et al., 1994; Takayama et al., 1995; 
Lacronique et al., 1996). Recently it has been shown that there are two distinct apoptotic 
pathways downstream of Fas, one of which is blocked by Bcl-2, with the relative 
contributions of these pathways varying among different cells (Yang et al., 1997). We found 
no evidence that Bcl-x or Bax influences the susceptibility of CNS inflammatory cells to 
apoptosis. As the expression of all of these apoptosis-regulating molecules is increased in 
activated T cells (Broome et al., 1995b; Brunner et al., 1995; Dhein et al., 1995; Ju et al., 
1995), and yet only Fas+ and Fas-L+ cells selectively undergo apoptosis, these results indicate 
that Fas/Fas-L interactions, and not merely cellular activation per se, are responsible for T cell 
apoptosis in the CNS in EAE.  
Expression of these proteins may be modulated by cellular interactions in the CNS. In EAE, 
previously activated MBP-reactive T cells entering the CNS may re-encounter MBP peptides 
on the surface of bone marrow-derived cells such as macrophages or microglia (Craggs and 
Webster, 1985; Frei et al., 1987; Myers et al., 1993), or on parenchymal cells such as 
astrocytes (Fontana et al., 1984; Myers et al., 1993). T cell receptor cross-linking, even in the 
absence of costimulation, increases Fas expression and induces Fas-L expression on the T 
cells (Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995; van Parijs et al., 1996). T cell 
activation also results in an increase in Bcl-2 protein (Broome et al., 1995a), but this is 
dependent upon continued exposure to interleukin-2 (IL-2) (Deng and Podack, 1993; Broome 
et al., 1995a; Mueller et al., 1996) and other cytokines which signal through the -chain of 
the IL-2 receptor (Akbar et al., 1996). If autoreactive T cells re-encounter antigen presented 
by non-professional APCs such as microglia or astrocytes that are unable to deliver 
costimulatory signals, the production of IL-2 will wane. This would then lead to a 
downregulation of Bcl-2 expression and may predispose the T cells to Fas-mediated 
apoptosis.  
The proportions of V 8.2+ T cells expressing Fas or Fas-L increased markedly during the 
later recovery phase of the disease. This may be due to enhanced activation of autoreactive T 
cells newly entering the CNS. Increased activation of autoreactive T cells in the CNS might 
occur as a result of an increased availability of myelin antigens following demyelination and 
the increased microglial expression of class II major histocompatibility complex molecules 
that occurs during and after recovery from EAE (Matsumoto et al., 1986; McCombe et al., 
1992). This raises the possibility that activation-induced T cell apoptosis may, as we have 
previously suggested (Pender et al., 1992), be an ongoing process that contributes to the 
tolerant state that develops after an attack of acute EAE (Willenborg, 1979). Understanding 
this process and how it might fail in chronic autoimmune disorders may lead to a better 
understanding of diseases such as multiple sclerosis. 
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